Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial
Latest Information Update: 14 Dec 2023
Price :
$35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 14 Dec 2023 Status changed from active, no longer recruiting to completed.
- 24 May 2022 Planned End Date changed from 31 Dec 2022 to 1 May 2023.
- 24 May 2022 Planned primary completion date changed from 31 Dec 2022 to 1 May 2023.